Genedata at Bio-IT World Announces tranSMART Integration with Genedata Analyst

Pfizer/Genedata integration project enhances tranSMART with sophisticated data analysis and data loading capabilities based on Genedata Analyst™, the premier life science data analysis platform

Basel, Switzerland, April 22, 2014

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it will showcase the integration of Genedata Analyst with tranSMART at the 2014 Bio-IT World Conference & Expo (Boston, MA). The integration project, a successful co-development initiative between Genedata and Pfizer, enables translational scientists to enter, analyze, extract, and share high-dimensional omics data and low-dimensional clinical data within a single integrated platform. Additionally, the integration allows investigators to leverage the open data import architecture of Genedata Analyst to easily publish all types of omics data into tranSMART. Combining the data ware-house capabilities of tranSMART with the advanced analytical tools of Genedata Analyst provides inter-disciplinary teams with an integrated research collaboration and data analysis platform. Enhancements to the core tranSMART system, developed as part of the integration project, will be contributed to the tranSMART community by Genedata. The integrated platform, a standalone product offering from Genedata, will be demonstrated by Genedata at the Bio-IT World Conference (Seaport World Trade Center; Boston, MA; Booth #232; April 29- May 2, 2014).

Making tranSMART Smarter with Genedata Analyst

tranSMART is an open-source knowledge management platform for translational science data sets, which incorporates high-dimensional data generated by omics experiments. These high-volume data sets are usually stored in file formats specific to the corresponding experimental methods from which they were derived. Integrating high-dimensional data sets and exporting data for analysis into other data analysis tools is often a time-consuming and error-prone process. Pfizer and Genedata addressed this challenge with the Genedata Analyst - tranSMART integration project. The project tightly integrates Genedata Analyst with tranSMART to create an interoperable platform, which enables Pfizer investigators to analyze tranSMART data using Genedata Analyst’s wide-ranging data analysis tools in a streamlined process.

Genedata Analyst is the established platform for the integration and interpretation of big experimental data sets in pharmaceutical R&D. It offers rigorous statistical algorithms, interactive data analysis tools, intuitive visualizations, and flexible plugin APIs. With these capabilities, Genedata Analyst targets the data analysis requirements of biologists and other scientists who need sophisticated statistical capabilities yet lack statistical expertise.

“More and more, clinical trials are collecting omics data including genetics and transcriptomics. While tranSMART has the ability to analyze omics data, the analytical and visualization tools in Genedata Analyst are far more sophisticated and provide significant value to our scientists,” noted Jay Bergeron, director, Translational and Bioinformatics, at Pfizer. “The integration of tranSMART and Genedata Analyst provides a single solution for exploratory data analysis and hypothesis generation. It allows scientists to mine clinical data for insights into human disease and to associate clinical data with high dimensional omics data.”
The Genedata Analyst - tranSMART integration project creates a truly bi-directional information exchange between Genedata Analyst and the tranSMART data warehouse. Leveraging the advanced data integration and mapping capabilities of Genedata Analyst, scientists can now easily perform meta-analyses across translational studies. For the first time, at the click of a button, the Genedata Analyst - tranSMART integration will:

  • Reduce the time (to minutes) to import,  export, reduce, integrate, and format data for analytical processing
  • Eliminate error-prone manual processes by automating the data transfer between tranSMART and external data analysis tools
  • Offer researchers enterprise-wide access to tranSMART’s rich data sets using an established enterprise analytical platform, which helps to standardize complex data analytics processes
  • Give bioinformaticians access to exploratory clinical data stored and managed in tranSMART

“We are very excited about our successful collaboration with Pfizer to establish this integrated platform for translational science,” said Dr. Othmar Pfannes, CEO of Genedata. “For over a decade, Genedata has delivered scalable solutions for the integrated analysis of omics data, and we remain committed to extend our support to translational sciences with powerful data analytics solutions. With Pfizer, we have enhanced tranSMART’s strength as a data warehouse, which will enable the growing tranSMART user community to efficiently analyze increasingly complex clinical trial data in the search for better drugs and treatment options.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.